AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.
In this episode, we discuss:
- Lars’ experience overcoming Treatment-Resistant Depression with psilocybin
- The nuances of clinical trials and psilocybin dosing protocols
- Compass Pathways’ Intellectual Property strategy
- What additional indications and therapies Compass Pathways is interested in
Links to topics discussed in this episode:
Compass Pathways, Lars Wilde
COMP360
SSRI, SNRI
Christian Angermayer, Robin Carhart-Harris, Michael Pollan
Vivaneo
Quercis Pharma
TRD (Therapy-Resistant Depression)
Compass Phase 2B Trial
Jazz Pharmaceuticals
Compass Pathways 2 US patents
Oregon Psilocybin Therapy Measure 109
Read the transcript here.
Watch episode 10 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Hosts: Matias Serebrinsky and Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh
Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional music: River Meditation by Jason Shaw and Thea by Muted Circus
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode